Since the first precise definition of myelodysplastic syndromes (MDS) in 1982, prognostication of this disease has been a matter of debate. It very quickly became clear that the prognosis of MDS patients cannot be assessed by a single parameter, although the prognostic impact of the FAB classification, which is based on bone marrow morphology, is still impressive. This reflects the fact that th...
